Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), March 2025 The Doxy-PEP Decision Making Tool supports prescribing doxycycline post-exposure prophylaxis (Doxy-PEP) to gay and bisexual men and transgender women at increased risk of syphilis. Suitable patients include those with recent syphilis or other STI diagnoses, periods of increased risk, or who wish to protect...
UK Health Security Agency, 30 October 2024 The UK Health Security Agency (UKHSA) has detected a single confirmed human case of Clade Ib mpox. The risk to the UK population remains low. This is the first detection of this Clade of mpox in the UK. It is different from mpox Clade II that has been circulating at low levels in the UK since 2022, primarily among gay, bisexual and other men-who-have-sex...
Improving our understanding of HIV notifications among people from Culturally and Linguistically Diverse backgrounds in Australia By Ela Naruka, Research Officer, Kirby Institute, October 23, 2024 Over the past decade (2014-2023), there has been a 21.5% increase in HIV notifications among people from CALD backgrounds. In 2014, there were 306 notifications (28% of total notifications), which rose...
Kirby Institute, UNSW |Media release | Published on 04 Sep 2024 Over the last decade, HIV diagnoses in Australia have continued to follow a downward trend, according to new data released today by the Kirby Institute at UNSW Sydney. While there were 722 new HIV diagnoses reported nationally in 2023 – up from 553 in 2022 – the researchers still reported a lower number of annual cases compared to...
Australian Research Centre in Sex, Health and Society, La Trobe University, April 2024. Rainbow Realities provides a synthesis of pre-existing findings as well as more than 50 new analyses derived from the data of six surveys of LGBTQA+ populations in Australia. These are: Private Lives 3, Writing Themselves In 4, SWASH , Trans Pathways, Walkern Katatdjin (Rainbow Knowledge) and Pride and...
van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, Smit C, Rauch A, Braun DL, Jarrin I, Berenguer J, Lazarus JV, Lacombe K, Requena MB, Wittkop L, Leleux O, Salmon D, Bonnet F, Matthews G, Doyle JS, Spelman T, Klein MB, Prins M, Asselin J, Stoové MA, Hellard M; InCHEHC study group. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus...